Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones

Free Radical Biology and Medicine

Volumn 46, Issue 2, 2009, Pages 253-262

  Gaikwad, Nilesh W ^a   Yang, Li ^a   Rogan, Eleanor G ^a   Cavalieri, Ercole L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Enzyme substrate complex; Estrogen ortho quinones; Kinetics; LC MS; MALDI TOF; Melatonin; MT3; NQO2

Indexed keywords

2 QUINONE DERIVATIVE; BENZYLDIHYDRONICOTINAMIDE RIBOSIDE; CARCINOGEN; ESTRADIOL 3,4 QUINONE DERIVATIVE; ESTRADIOL DERIVATIVE; ESTROGEN; MELATONIN; NAD(P)H:QUINONE OXIDOREDUCTASE 2; NICOTINAMIDE; QUERCETIN; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CATALYSIS; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE; ESTROGEN METABOLISM; IONIZATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

ABSORPTION; CELL TRANSFORMATION, NEOPLASTIC; ESTRADIOL; ESTROGENS; HUMANS; MELATONIN; MODELS, CHEMICAL; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION; PROTEIN BINDING; QUERCETIN; QUINONE REDUCTASES; QUINONES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTRATE SPECIFICITY;

EID: 58049109067     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2008.10.029     Document Type: Article

References (35)

1. Long II D.J., and Jaiswal A.K. NRH:quinone oxidoreductase2 (NQO2). Chem. Biol. Interact. 129 (2000) 99-112
2. Nosjean O., Nicolas J.P., Klupsch F., Delagrange P., Canet E., and Boutin J.A. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem. Pharmacol. 61 (2001) 1369-1379
3. Burchiel S.W., Thompson T.A., Lauer F.T., and Oprea T.I. Activation of dioxin response element (DRE)-associated genes by benzo(a)pyrene 3,6-quinone and benzo(a)pyrene 1,6-quinone in MCF-10A human mammary epithelial cells. Toxicol. Appl. Pharmacol. 221 (2007) 203-214
4. Jaiswal A.K., Burnett P., Adesnik M., and McBride O.W. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry 29 (1990) 1899-1906
5. Wu K., Knox R., Sun X.Z., Joseph P., Jaiswal A.K., Zhang D., Deng P.S., and Chen S. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. 347 (1997) 221-228
6. Foster C.E., Bianchet M.A., Talalay P., Zhao Q., and Amzel L.M. Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry 38 (1999) 9881-9886
7. AbuKhader M., Heap J., De Matteis C., Kellam B., Doughty S.W., Minton N., and Paoli M. Binding of the anticancer prodrug CB1954 to the activating enzyme NQO2 revealed by the crystal structure of their complex. J. Med. Chem. 48 (2005) 7714-7719
8. Ross D., and Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol. 382 (2004) 115-144
9. Kiyohara C., Yoshimasu K., Takayama K., and Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet. Med. 7 (2005) 463-478
10. Bianco N.R., Chaplin L.J., and Montano M.M. Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem. J. 385 (2005) 279-287
11. Gaikwad N.W., Rogan E.G., and Cavalieri E.L. Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones. Free Radic. Biol. Med. 43 (2007) 1289-1298
12. Cavalieri E., Rogan E., and Chakravarti D. The role of endogenous catechol quinones in the initiation of cancer and neurodegenerative diseases. Methods Enzymol. 382 (2004) 293-319
13. Cavalieri E., Chakravarti D., Guttenplan J., Hart E., Ingle J., Jankowiak R., Muti P., Rogan E., Russo J., Santen R., and Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 1766 (2006) 63-78
14. Zahid M., Kohli E., Saeed M., Rogan E., and Cavalieri E. The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity. Chem. Res. Toxicol. 19 (2006) 164-172
15. Cavalieri E.L., Li K.M., Balu N., Saeed M., Devanesan P., Higginbotham S., Zhao J., Gross M.L., and Rogan E.G. Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 23 (2002) 1071-1077
16. Chakravarti D., Mailander P.C., Li K.M., Higginbotham S., Zhang H.L., Gross M.L., Meza J.L., Cavalieri E.L., and Rogan E.G. Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 20 (2001) 7945-7953
17. Mailander P.C., Meza J.L., Higginbotham S., and Chakravarti D. Induction of A.T to G.C mutations by erroneous repair of depurinated DNA following estrogen treatment of the mammary gland of ACI rats. J. Steroid Biochem. Mol. Biol. 101 (2006) 204-215
18. Zhao Z., Kosinska W., Khmelnitsky M., Cavalieri E.L., Rogan E.G., Chakravarti D., Sacks P.G., and Guttenplan J.B. Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol. Chem. Res. Toxicol. 19 (2006) 475-479
19. Nutter L.M., Zhou B., Sierra E.E., Wu Y.Y., Rummel M.M., Gutierrez P., and Abul-Hajj Y. Cellular biochemical determinants modulating the metabolism of estrone 3,4-quinone. Chem. Res. Toxicol. 7 (1994) 609-613
20. Nosjean O., Ferro M., Coge F., Beauverger P., Henlin J.M., Lefoulon F., Fauchere J.L., Delagrange P., Canet E., and Boutin J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 275 (2000) 31311-31317
21. Souza A.V., Visconti M.A., and Castrucci A.M. Melatonin biological activity and binding sites in human melanoma cells. J. Pineal Res. 34 (2003) 242-248
22. Mailliet F., Ferry G., Vella F., Thiam K., Delagrange P., and Boutin J.A. Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett. 578 (2004) 116-120
23. Schernhammer E.S., and Hankinson S.E. Urinary melatonin levels and breast cancer risk. J. Natl. Cancer Inst. 97 (2005) 1084-1087
24. Lenoir V., de Jonage-Canonico M.B., Perrin M.H., Martin A., Scholler R., and Kerdelhué B. Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat. Breast Cancer Res. 7 (2005) R470-R476
25. Shiu S.Y. Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. J. Pineal Res. 43 (2007) 1-9
26. Saeed M., Zahid M., Rogan E., and Cavalieri E. Synthesis of the catechols of natural and synthetic estrogens by using 2-iodoxybenzoic acid (IBX) as the oxidizing agent. Steroids 70 (2005) 173-178
27. Dwivedy I., Devanesan P., Cremonesi P., Rogan E., and Cavalieri E. Synthesis and characterization of estrogen 2,3-and 3,4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. Chem. Res. Toxicol. 5 (1992) 828-833
28. van Duijn E., Simmons D.A., van den Heuvel R.H., Bakkes P.J., van Heerikhuizen H., Heeren R.M., Robinson C.V., van der Vies S.M., and Heck A.J. Tandem mass spectrometry of intact GroEL-substrate complexes reveals substrate-specific conformational changes in the trans ring. J. Am. Chem. Soc. 128 (2006) 4694-4702
29. Vermeiren C.L., Pluym M., Mack J., Heinrichs D.E., and Stillman M.J. Characterization of the heme binding properties of Staphylococcus aureus IsdA. Biochemistry 45 (2006) 12867-12875
30. Felitsyn N., Peschke M., and Kebarle P. Origin and number of charges observed on multiply-protonated native proteins produced by ESI. Int. J. Mass Spectrom. 219 (2002) 39-62
31. Beck J.L., Colgrave M.L., Ralph S.F., and Sheil M.M. Electrospray ionization mass spectrometry of oligonucleotide complexes with drugs, metals, and proteins. Mass Spectrom. Rev. 20 (2001) 61-87
32. Winski S.L., Faig M., Bianchet M.A., Siegel D., Swann E., Fung K., Duncan M.W., Moody C.J., Amzel L.M., and Ross D. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. Biochemistry 40 (2001) 15135-15142
33. Li R., Bianchet M.A., Talalay P., and Amzel L.M. The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 8846-8850
34. Boutin J.A., Chatelain-Egger F., Vella F., Delagrange P., and Ferry G. Quinone reductase 2 substrate specificity and inhibition pharmacology. Chem. Biol. Interact. 151 (2005) 213-228
35. Asher G., Dym O., Tsvetkov P., Adler J., and Shaul Y. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol. Biochemistry 45 (2006) 6372-6378